Navigation Links
AVN944 in Medical Technology

Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial

GERMANTOWN, Md., June 13, 2007 /PRNewswire-FirstCall/ -- Avalon Pharmaceuticals, Inc. , today announced that it is will provide an update on the Phase I clinical trial of AVN944 in hematologic malignancies on Tuesday, June 19, 2007, after the close of the U.S. financial markets. The Company will a...

Avalon Pharmaceuticals to Present at the American Association for Cancer Research 2007 Annual Meeting

...valon Pharmaceuticals, Inc. , today announced that avn944 will be the subject of three poster presentations ...and in vivo experiments that reveal the effects of avn944 on blood vessel formation. The presentation will b...acific Time. Another poster that will discuss avn944 will be presented by the lab of Dr. Beverly Mitche...

Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial

...rly and refractory patients. Interim data indicate avn944 is well tolerated, has dose-dependent pharmacokine...ncouraged by the positive interim results from the avn944 trial," stated Michael Hamilton, M.D., Avalon Phar...tiate multiple Phase II studies." Background: avn944 is an oral small molecule drug that inhibits inosi...
AVN944 in other areas

Avalon Pharmaceuticals Initiates AVN944 Phase I Clinical Trial in ...

We believe that AVN944 has the potential to offer oncologists and cancer patients ... of the safety and tolerability of AVN944 in adult patients with advanced ...

Microsoft Word - 090705_Avalon

Drug Administration (FDA) for their lead candidate, AVN944 for treatment of cancer. ... AVN944 is an inhibitor of the enzyme inosine monophosphate ...

Avalon Updates The AVN944 Phase I Hematologic Malignancies Trial

Avalon Pharmaceuticals, Inc. (Nasdaq: AVRX), today announced that it is will provide an update on the Phase I clinical trial of AVN944 in hematologic malignancies on ...

FOR IMMEDIATE RELEASE Contacts: Avalon Pharmaceuticals, Inc. Noonan ...

AVN944 is an orally bioavailable inhibitor of inosine monophosphate dehydrogenase 1 and 2 ... of sensitivity and resistance to AVN944 ... benefit from AVN944. ...

Avalon Pharmaceuticals Announces the Activation of IND for AVN944 for ...

AVN944 is an oral, small molecule inhibitor of the enzyme inosine monophosphate ... AVN944 was in-licensed by Avalon from Vertex Pharmaceuticals Incorporated ...

Summary of AVALON PHARMACEUTICALS INC - Yahoo! Finance

... therapeutics, and the in-license and development of AVN944. ... AVN944 was in-licensed by us from Vertex in February 2005. Financial Operations Overview ...
Other Tags
(Date:7/23/2014)... The National Quality Forum’s (NQF) Board ... for a defined period that will assess the ... measures for sociodemographic factors, prior to making a ... can be socioeconomic, e.g., income, education, and occupation, ... Growing evidence shows that sociodemographic factors may ...
(Date:7/23/2014)... 23, 2014 In preparation for National ... Millennium Treatment Group is providing tips on choosing a ... society ever since man first figured out the process ... has existed since shortly thereafter. Its basis lies in ... then developing a way to combat that problem while ...
(Date:7/23/2014)... Steven Reinberg HealthDay ... -- Many obese and overweight American children and teens ... is fine, U.S. health officials reported Wednesday. "Being ... such as high blood pressure, high cholesterol and diabetes," ... the U.S. Centers for Disease Control and Prevention,s National ...
(Date:7/23/2014)... Inventor and entrepreneur Delegate Joe T. ... the gas pump – sharing his passion for technology ... at Noon. , With 24 patents granted and three ... anyone in the General Assembly since Thomas Jefferson. Inventions ... marker as seen on television, an instrument for measuring ...
(Date:7/23/2014)... WHAT: The National Institute of Biomedical Imaging and ... Investigator Symposium on July 30, 2014 on the NIH ... new investigators covering a wide breadth of NIBIB-funded research. ... Adam Cohen, Harvard, Engineering Microbial Rhodopsins as Optical Voltage ... Testing Fluorescently Labeled Probes for Nerve ...
Breaking Medicine News(10 mins):Health News:NQF Board Approves Trial Period to Test Impact of Risk Adjustment of Performance Measures for Sociodemographic Factors 2Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 2Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 3Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 3Health News:Celebrating Innovation and Invention 2
(Date:7/23/2014)... its grip is affecting more than the color of people,s ... a heat-loving amoeba commonly found in warm freshwater bodies, such ... made warmer than usual this year. , A 9-year-old Kansas ... after swimming in several area lakes. The amoeba enters the ... the brain. Nose plugs can lower the odds of this ...
(Date:7/23/2014)... blow fly Chrysomya megacephala is commonly found ... to determine the time of death, referred to as ... form of C. megacephala from Tamil Nadu ... features and molecular characterization through generation of DNA barcoding. ... the open access Biodiversity Data Journal . , ...
(Date:7/23/2014)... around the world by 2050, according to one of ... Change (IPCC), may be advantageous to the physiology and ... of forage plants such as Stylosanthes capitata Vogel ... countries such as Brazil., The conclusion is from a ... Biology at the Ribeiro Preto Faculty of Philosophy, Sciences ...
Breaking Biology News(10 mins):Diseases of another kind 2Dead body feeding larvae useful in forensic investigations 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 3An increase in temperature by 2050 may be advantageous to the growth of forage plants 4
Other Contents